About
The RIGHT Study
Reducing Inflammation for Greater Health Trial
Older adults can have slightly elevated markers of inflammation on a blood test, but no signs of infection or illness. However, elevated markers of inflammation are related to decreased energy and walking ability.
What can be done about age-related inflammation?
There is no proven way to address age-related inflammation.
RIGHT is the first research study to test whether a medication that blocks inflammation can improve walking ability and overall function.
Participants
Who is eligible?
RIGHT is open to men and women aged 70 years or older who meet the eligibility criteria and are able to attend monthly visits for 7 months.
What is involved?
If you qualify for the RIGHT Study, you will be randomly assigned (much like the flip of a coin) to one of two groups: active drug or placebo. The placebo is given in the same way as the active drug but contains no medicine. You will receive an injection of clazakizumab (5 mg) or placebo in your upper arm every 4 weeks for 6 months with phone calls in between injection visits. The injection is administered so that neither you nor the investigators of the study know if you are receiving the active drug or placebo. Other health assessments such as questionnaires, physical tests, blood samples, chest x-ray, Magnetic Resonance Imaging (MRI) test, and a walking-based treadmill test to measure oxygen consumption and carbon dioxide production.
Compensation
If you are able to complete all study visits, you may receive up to $350. Parking is covered when participating in the study.
Contact
Connect with the RIGHT Study
If you are interested in participating in RIGHT, please complete the Participant Interest Form below or contact the research staff at the University of Pittsburgh.